Benzinga - by Ryan Gustafson, Benzinga Staff Writer.
Cardiff Oncology, Inc. (NASDAQ: CRDF) shares are trading higher Tuesday after-hours after the company announced clinical data in pancreatic cancer and small cell lung cancer, including single-agent activity from onvansertib monotherapy.
What To Know: On Tuesday, Cardiff Oncology announced positive clinical data with onvansertib monotherapy and combination therapy in its ongoing trials in metastatic pancreatic ductal adenocarcinoma and small cell lung cancer. Additionally, the company expressed plans for a mPDAC first-line investigator-initiated trial of the combination of onvansertib plus standard-of-care.
"We are excited that the data released from these trials, in two challenging cancers with low survival rates, expands the opportunity for onvansertib beyond our lead program in RAS-mutated mCRC," said Mark Erlander, CEO of Cardiff Oncology.
"In pancreatic cancer, the strength of the data provides a clear rationale for a first-line trial using onvansertib in combination with standard of care, which we believe provides the greatest opportunity for a positive impact on patients. In small cell lung cancer, we are encouraged to observe single-agent activity with onvansertib monotherapy in this difficult-to-treat extensive stage refractory setting."
Related Link: Why MillerKnoll Stock Surged After Hours
CRDF Price Action: Shares of CRDF were up 6.7% at $1.73 in the after-hours session at the time of publication, according to Benzinga Pro.
Image by Michal Jarmoluk from Pixabay.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.